Lv01
0 积分 2024-10-27 加入
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
4小时前
已完结
Lobectomy verses Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation
3个月前
已完结
Assessment of Operability and Resectability in Lung Cancer
4个月前
已关闭
Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint
5个月前
已完结
The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer
5个月前
已完结
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer
5个月前
已完结
Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy
6个月前
已完结
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
6个月前
已完结
The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population
7个月前
已完结
The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population
7个月前
已关闭
皖公网安备34019202002308
